Trial Profile
Study of abiraterone acetate plus prednisone (AA+P) or enzalutamide (ENZ) in metastatic castrate resistant prostate cancer patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2017
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Enzalutamide; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 18 Feb 2017 Results (n=2540) presented at the 2017 Genitourinary Cancers Symposium.
- 16 Aug 2016 New trial record